Trials / Completed
CompletedNCT03266822
T-cell Subsets in Rheumatoid Arthritis Patients on Long-term Anti-TNF or IL6-receptor-blocker Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 122 (actual)
- Sponsor
- Szeged University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Data on the impact of biological therapies, especially of IL6-blocker treatment, on the T-cell phenotype in rheumatoid arthritis (RA) are limited, inconclusive, and mainly involve short-term follow-up. Here, the investigator prospectively measure the percentages of 15 circulating T-cell subtypes using flow cytometry. The investigators aim to obtained transversal and longitudinal data in 30 anti-TNF responders, 19 secondary anti-TNF-non-responders, 43 IL6R-antagonist-responders before, 8 weeks and, after, at least, 6 months of biological therapy. These are then compared with results obtained in early, untreated RA patients and gender-and-age matched healthy controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Observational study |
Timeline
- Start date
- 2013-01-02
- Primary completion
- 2015-12-30
- Completion
- 2016-05-31
- First posted
- 2017-08-30
- Last updated
- 2017-08-30
Source: ClinicalTrials.gov record NCT03266822. Inclusion in this directory is not an endorsement.